Illumina Registers MiSeqDx for Clinical Use in South Korea | GenomeWeb

NEW YORK (GenomeWeb) – Illumina has received a product approval certificate for clinical use for its MiSeqDx instrument and MiSeqDx Universal kit from South Korea's Ministry of Food and Drug Safety.

The registration allows Illumina to sell its instrument to clinical laboratories in South Korea, and will "accelerate the process for us to get other Illumina clinical products into this market in the future," Jason Kang, Illumina's commercial leader in South Korea, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.

Sponsored by

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.